Brolucizumab 12-And 16-Week Fixed Dosing Potential in Neovascular Amd: A Post Hoc Evaluation of Data from the Hawk and Harrier Trials
AuthID
P-00X-11W
P-00X-11W
© 2024 CRACS & Inesc TEC - All Rights Reserved Política de Privacidade | Terms of Service